Molecular Partners AG Sponsored ADR
MOLN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.9%, EPS grew 34.3% and free cash flow grew 23.8%, each against the same quarter a year earlier.
Follow MOLN
Molecular Partners AG Sponsored ADR (MOLN) EV/Sales
As of 16 October 2026, Molecular Partners AG Sponsored ADR (MOLN) trades at a EV/Sales of 9.2×. Over the past ten years it has ranged from −12.3× (October 2023) to 83.0× (January 2022); the current reading is higher than 85% of that period. That is in line with the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −1.4× | — |
| FY2023 | −9.1× | — |
| FY2022 | −0.2× | — |
| FY2021 | 44.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | −1.4× | — |
| Sep 2024 | 0.4× | (93.96%) |
| Jun 2024 | 7.3× | — |
| Mar 2024 | −8.0× | — |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NBP NovaBridge Biosciences compare | −3.8× |
| NKTX Nkarta, Inc. compare | n/m |
| MSLE Satellos Bioscience Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| MENS Jyong Biotech Ltd. compare | n/m |
| CDXS Codexis, Inc. compare | 1.2× |
| ALXO ALX Oncology Holdings Inc. compare | 8.4× |
| MOLN Molecular Partners AG Sponsored ADR | 9.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)